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Summary A tumour cloning system was used to cultivate breast cancer specimens. Fifty-six percent of 87
samples were adequate for evaluation, showing clonal growth in about one third (35%). Effusions yielded
significantly better growth than solid specimens, the median colony numbers being 64 and 18 respectively. An
attempt was made to examine whether there was any association between parameters accepted as prognostic
factors for breast cancer and clonal growth in vitro. No correlation was found between preoperative tumour
burden, histopathologic grading, menopausal status or overall survival and clonal growth in vitro, whereas we
observed an inverse trend between progesterone receptor content of the tumours and their growth potential
(P<0.01). In those few cases where in vitro and in vivo data could be compared, a high accuracy of the
predicted sensitivities was found with respect to chemotherapy, but not in relation to hormonal treatment. A
statistically significant higher overall chemosensitivity was associated with the absence of oestrogen receptors
(P<0.01).
Optimal management of women with breast cancer
is one of the most challenging problems facing
oncologists today. Beyond clinical trials, efforts
have been made to establish laboratory parameters
and to develop test systems to provide information
on prognosis and response to therapy, for the
optimization of treatment. To date, determination
of hormone (oestrogen, progesterone) receptor
levels has proved useful in predicting response of
individual patients to hormone treatment (Osborne
et al., 1980; Paridaens et al., 1980; Hilf et al., 1980).
After the publication of Salmon et al. (1978) on the
"differential sensitivities of human tumour stem
cells to anticancer drugs", the capacity to predict
the response of individual tumours to a given
cytotoxic drug seemed to be more feasible.
Till now, there have been only a few reports in
the literature on the use of the human tumour
cloning assay (HTCA) for pretherapeutic
assessment of the chemosensitivity of breast cancer
- most of them reflecting a rather reserved
acceptance (Pavelic et al., 1980; Sandbach et al.,
1982; Schlag et al., 1982; Benard et al., 1983;
Touzet et al., 1983; Jones et al., 1984; Dittrich et
al., 1984).
On the basis of our own results, we attempted to
appraise the HTCA for its clinical value in
mammary carcinoma. Special emphasis has been
placed on the interrelationship of risk factors for
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women with breast cancer, such as tumour stage,
grading, hormone receptor level or menopausal
status and the in vitro growth pattern. Furthermore
we endeavoured to analyze whether colony growth
provided reliable information on patients' survival.
The practicability of the test system and its
accuracy in predicting individual responsiveness to
chemo- and hormone-therapy were examined.
Materials and methods
Eighty-seven specimens from 74 different patients
were sent to our laboratory. About two thirds of
these were biopsies and one third originated from
effusions.
Sample collection, tumour processing, cultivation
and drug testing were performed according to the
method of Hamburger & Salmon (1977) with
recently described modifications (Dittrich, 1984;
Dittrich et al., 1984).
Processing oftumour specimens
Tumour tissue was disaggregated by mincing with
scissors into small pieces. The tissue fragments were
then incubated in an enzyme cocktail (0.15%
collagenase, type IA, Sigma and 0.015% DNase,
type I, Sigma) at 37°C for 1-2h. At completion of
the enzymatic dissociation procedure the cells were
washed, resuspended in McCoy's 5 A medium and
pressed through a 25pm mesh filter. Cell counts
and determination of cell viability using the trypan
blue dye exclusion method were performed
simultaneously in a Neubauer's haemocytometer.
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The cell concentration was adjusted to the standard
of 3 x106 mononuclear cells ml-1 for triplicates.
Effusions were centrifuged at 2000r.p.m. for
20min. The resulting pellets were resuspended in
McCoy's 5A medium and pressed through a 25pm
mesh filter. Determination of total and viable cell
count and adjustment to the standard cell concen-
tration were executed as described above.
Drug testing
The following drugs, which were kindly provided
by various compamnes, were used in our
experiments: aclacinomycin A (Behring Werke,
FRG); adriamycin (Farmitalia-Montedison, Italy);
cisplatin (Bristol Myers Laboratories, USA); 5-
fluorouracil (Hoffmann-La Roche Laboratories,
Switzerland); methotrexate (EBEWE Laboratories,
Austria, and Cyanamid Laboratories, USA);
tamoxifen (ICI Laboratories, UK); vincristine (Eli
Lilly Laboratories, USA).
Aliquots of the cell suspension were distributed
over vials. The final concentration was adjusted to
106 cellsml- by adding medium only to the
controls and to those vials taken for continuous
exposure or by adding drug dilutions plus medium
to the vials taken for 1 h drug exposure. Several
drug concentrations achievable in man (Alberts et
al., 1980) of each chosen drug were tested on every
tumour. After incubation of drug tests and controls
at 37°C in a humidified 5.5% CO2 atmosphere for
1 h - the time chosen for schedule independent
and/or chemically and biologically unstable
substances - samples were washed twice in medium
and cultivated. Those drugs and hormones being
schedule dependent and/or chemically and
biologically stable were tested by exposing the cells
to the drug dilutions for the entire incubation
period (Ludwig & Alberts, 1984).
Culture
Aliquots of cells resuspended in 0.3% agar in
enriched CMRL 1066 medium were plated in
35mm petri dishes over an underlayer of 0.5% a'gar
in enriched McCoy's 5A medium. The final con-
centration was 5 x 10o cells per petri dish. After
examination for clumps, the petri dishes were
incubated in a humidified 5.5% CO2 atmosphere at
37°C for 2 to 3 weeks. Control plates were
routinely reexamined to assess the optimal time for
study evaluation.
Test evaluation
Colonies were defined as aggregates of 40 or more
cells originating from a single cell by cell division
(Hamburger & Salmon, 1977). Evaluation of the
drug studies was done counting established colonies
under an inverted microscope. Petri dishes with 5
or more colonies were considered positive, but only
cultures with 30 or more colonies in the controls
were adequate for drug evaluation. Reduction of
colony growth by 70% or more in the drug tests
compared to the controls was considered to
represent drug sensitivity.
Identification oftumour cells
Permanent slides of the established cultures
prepared according to the method of Salmon &
Buick (1979) were routinely compared with the
cytocentrifuge slides made of each original cell
suspension for morphologic evaluation and
documentation. A nuclear grading system similar to
Bloom's histologic grading (Bloom, 1950a,b) was
used to obtain data enabling comparison between
cytology and histology. Additional methods used
for confirming the malignant nature of the cells
from the original cell suspensions and from those
growing as colonies were chromosome analysis
(Trent, 1980) and in a few cases, transmission
electron microscopy (Persky et al., 1982).
Statistical methods
Comparisons between two groups of data which
were not distributed normally were done using
Wilcoxon tests. For correlation, the Spearman rank
correlation was chosen. Frequencies were evaluated
by x2 tests.
Results
Forty-nine out of 87 samples (56%) sent to our
laboratory were accepted for evaluation. Reasons
for exclusion of 38 specimens are detailed in Table
I. Whereas all of the exclusions of body fluids were
due to negative cytology, inadequate cell viability
(<30% viable cells by the trypan blue exclusion
method) was the main reason for biopsies being
unsuitable for evaluation. The origin of the test
material is described on Table II.
Clonal growth was observed in only 17/49 (35%)
of all adequate breast cancer specimens; effusions
providing sufficient growth in more than three
quarters of cases, and biopsies in only one of four
cases. The overall growth of effusions was
significantly higher than that of biopsies (P<0.01,
x2=10.04). The median colony number of the
effusions was 64 and that of the biopsies, 18. The
mean cloning efficiency for all tests was 0.0111%
(median 0.0092% range: 0.0010%-0.0486%; Table
III).
With a median of 93%, the cell viability of the
effusions (mean: 87%, range: 48-99%) wasHUMAN TUMOUR CLONING ASSAY IN BREAST CANCER
Table I Criteria for exclusion of tumour specimens from
evaluation
Negative histologic/cytologic findings 13/38 (35%)
Inadequate cell viability (<30%)a 18/38 (46%)
Insufficient tumour material 6/38 (16%)
Contamination 1/38 (3%)
aCell viability was determined using the trypan blue dye
exclusion method.
Table II Origin of test material
Biopsies (55%) 27/49
Primary tumours 22
Local recurrences 2
Metastases 3
Effusions (45%) 22/49
Pleural effusions 16
Ascites 4
Pericardial effusions 2
Table III Growth ofbreast cancer specimens in the HTCA
Biopsies Effusions Total
n median range n median range n median range
Colony number
G. overalla 4 18 5-30 13 64 9-243 17 46 5-243
G. sufficientb 1 - 10 67 32-243 11 65 30-243
Cloning efficiencyc
G.overall 4 0.0035 0.0010-0.0060 13 0.0128 0.0018-0.0486 17 0.0092 0.0010-0.0486
G. sufficient 1 - 10 0.0133 0.0064-0.0486 11 0.0130 0.0060-0.0486
'G. (growth) overall comprises all grown specimens with . 5 colonies per control plate.
bG. (growth) sufficient refers to grown specimens with . 30 colonies per control plate.
'Cloning efficiency (°/)=
No. of colonies
x 100. No. of mononuclear cells
significantly higher (P<0.01) than that of the
biopsies which had a median of 55% (mean: 57%,.
range: 33-99%). The viability of the specimens
providing colony growth was significantly higher
than that of the non-growing samples (P<0.01).
This dependence of growth on cell viability was
underlined by the positive correlation between
viability and cloning efficiency (r5 =0.48; P<0.05).
In the following section we attempt to examine
colony growth in relation to established risk factors
for women with breast cancer.
Although growth occurred more frequently from
biopsies attained from advanced tumours,
correlation with tumour stage was not significant.
Furthermore, no association was found between
clonal growth and the corresponding histopatho-
logic grading in our specimens (n =22).
Regarding menopausal status no significant dif-
ferenceingrowth orlackofgrowth wasfoundbetween
premenopausal (n = 11) and postmenopausal
(n =32) women in our study. In addition, hormone
receptor levels of the tumours of 38 patients were
determined. There seemed to be a negative relation-
ship between progesterone receptor (PgR) level and
growth, but this did not reach statistical signifi-
cance (P<0.1) (Table IV).
Colony growth in the HTCA has been discussed
as a possible risk factor for survival, at least
regarding other malignancies (Mattox & Von Hoff,
Table IV Hormone receptor level-related growth
ofbreast cancer specimens in the HTCA
Hormone receptor status Growth in the H1CA
PgRa E2Rb Positivec Negatived
+ + 2 8
+ - 0 5
- + 3 4
- - 6 10
aProgesterone receptor level: +: _10 fmolmg-1
cytosol protein, -: <10 fmolmg-1 cytosol protein.
bOestrogen receptor level: +:.10fmolmg-
cytosol protein, - : < IOfmolmg- cytosol protein .5 S colonies in the controls.
d5<5 colonies in the controls.
1980; Durie et al., 1983). In our material no
association was found between in vitro growth of
the tumour specimens and the survival of the
corresponding patients.
A total of 129 single drug tests could be
performed on specimens from 14 different patients.
In vitro test results of samples of patients treated by
first or second line chemotherapy are illustrated
separately in Figure 1. The single drug response
rates in vitro corresponded well with the reported
clinical single drug response rates in the case of
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ADR 5-FU
n=25 n=13
U1)
c
CD
4 9 4 8 4 3 4 2 2 3 3 3 2 2 2 2 3 3 13 1 3 2 n
Figure 1 Chemosensitivity of breast cancer specimens in vitro and reported equivalent monochemotherapy
response rates in vivo. The percentage of sensitivity observed in the in vitro assay is illustrated by columns.
Sensitivity of specimens of patients receiving first line therapy is shown in the dotted columns, that of samples
from women under second line chemotherapy is demonstrated by the striped columns. The following drug
concentrations (C1,2) wereusedfortesting: adriamycin (ADR): C1 =0.1 gmI 1,C2 =0.01 pgml-1; 5-fluorouracil
(S-FU): C1 = 10.0 jigmP 1, C2 = 1.OpgmP1'; methotrexate (MTX): C1 =0.2aegmM X, C2 = 0.01 Cgmg 1;
vincristine (VCR): C1 =0.05Pgml-1, C2=0.0005 gml-1; aclacinomycin A (ACM): C1 =O.1pgml-1;
cisplatin (DDP): C1=O.1lgml-P, C2=0.Olggml '; tamoxifen (TAM): Cl=10-6M. The numbers (n) of
tests performed of the single items are indicated below the corresponding columns.
adriamycin and 5-fluorouracil, whereas in the case
of methotrexate agreement for the first line therapy
was found only at the lower in vitro drug level.
Vincristine, aclacinomycin and cisplatin did not
correspond well, neither at the higher nor at the
lower test concentration. For most of the drugs the
higher test concentration showed increased
sensitivity rates in vitro. Monochemotherapy
response rates for first line therapy (Hellman et al.,
1982; Kolaric & Roth, 1983; Oka, 1978) are
represented by horizontal bars in Figure 1.
Table V Sensitivity of breast cancer specimens to
tamoxifen with regard to their hormone receptor status
PgRa E2Rb RC Sd
+ + 2 1
+ - 1 1
- + 3 0
- - 1 0
ap R=progesterone receptor level: += >lOfmol
mg cytosol protein; -= <10fmolmg1cytosol
protein.
bE2R =oestrogen receptor level: + = _ 10fmolmg-
cytosol protein;-= <10fmol mg1 cytosol protein.
CR =resistant: colony survival >30% of control
count.
dS =sensitive: colony survival 30% of the control
count or less.
The in vitro response rate of 15% for tamoxifen
was very low with regard to the clinical results
(McGuire et al., 1977). In 9 of 13 established
tumour specimens tested against tamoxifen we
obtained the relevant hormone receptor levels, which
showed an uncharacteristic distribution (Table V).
Hormone receptor level-related chemosensitivity
is demonstrated on Table VI. Resistance to various
Table VI Chemosensitivity in relation to hormone
receptor status in breast cancer
E2Rd RgRe Na Rb(%) SC(%)
+ + 24 22 (92) 2 (8)
+ - 29 29 (100) 0 (0)
- + 14 9 (64) 5 (36)
- - 16 2 (12) 14 (88)
aNo. of single drug tests.
bR =resistant: colony survival >30% of the
control count.
CS=sensitive: colony survival 30% of the control
count or less.
dE2R=oestrogen receptor level: + = _ IOfmol
mg-' cytosol protein; -= <10fmolmg-1 cytosol
protein.
CPgR=progesterone receptor level: + = .10fmol
mg-' cytosol protein: -= <10fmolmg- cytosol
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cytotoxic drugs was found in 92% and 100% of the
oestrogen receptor (E2R) positive, but only in 12%
and 64% of the E2R negative samples (P<0.01).
Comparison between in vitro prediction and
clinical course could be made in 6 patients only. In
all other cases, the cytotoxic drugs tested were not
the same as those given as therapy. In 4/4 cases
resistance prediction was correct, and in 2/2 cases
sensitivity was accurately predicted.
Discussion
There are enormous discrepancies in most of the
scant data on the use of HTCA in breast cancer
sensitivity testing. Many of the differences are the
result of varying definitions and interpretations of
the fundamental notions about the assay system
itself. Our results will be discussed relative to those
reported in literature.
Even if our median colony number of 46 is quite
comparable to that of Sandbach et al. (1982), who
reported on 225 patients, and even if our
percentage of sufficient growth (22%) appears
equivalent to that of Jones et al. (1984) (27%), we
have to take into consideration that similar values
may mirror divergent results. The data reported by
us are based on the definition of a colony as an
aggregate of 40 or more cells originating from a
single cell by replication (Hamburger & Salmon,
1977). Other reports on this topic are based on four
different definitions of a colony - ranging from a
minimum of 20 to a minimum of 50 cells
originating from a single tumour cell (Kern et al.,
1982; Sutherland et al., 1983; Touzet et al., 1982;
Sandbach et al., 1982). The discrepancies in growth
obtained by different authors are less surprising
when initial 'standardized' materials are compared.
Cloning efficiencies may relate to nucleated cells
only (Jones et al., 1984; Sutherland et al., 1983;
own results), to viable cells (Bernard et al., 1983;
Sandbach et al., 1982), or even to viable tumour
cells (Schlag et al., 1982; Kern et al., 1982).
The continuous search for parameters which
could assist in the accurate prediction of prognosis
led to the establishment of the TNM system.
Sutherland et al. (1983) found no correlation
between the TNM classification and the number of
colonies grown in the HTCA. The higher frequency
of growth among the tumours of more advanced
TNM-stages in our study did not reach significance
either. Histologic and cytologic grading are other
means of surveying the aggressiveness of a
neoplasm. In accordance with Benard et al. (1983)
we found no association between the histopatho-
logic grading and clonal growth in our material.
The data contrast markedly with the observation
made by Touzet et al. (1982), who did find a
significant positive correlation between colony
growth in vitro and tumour grade. Furthermore
colony growth in vitro seems to be independent of
the menopausal status.
Another acknowledged prognostic factor for
breast cancer patients is hormone receptor status.
In contrast to several authors who found no
correlation between the number of colonies and the
E2R level (Sutherland et al., 1983) or between in
vitro colony growth and the E2R level (Sandbach et
al., 1982; Benard et al., 1983), we found a negative
trend between PAR positive tumours and their
growth in culture (P<0.1). The absence of the
differentiation product, PAR may be considered an
indicator of shorter disease-free survival (Clark et
al., 1983) caused by more primitive cancer cells.
Their aggressiveness seems to be reflected by their
growth in the double layer agar system.
Additionally, colony growth in vitro has been
shown to represent an independent factor indicative
of patients' survival (Mattox & Von Hoff, 1980;
Durie et al., 1983). We found no correlation
between colony growth in vitro and patients'
survival in our study. Both Sutherland et al. (1983)
and Benard et al. (1983) found such relations, at
least for subgroups ofpatients.
The original aim of the creation of the HTCA
was to develop a tool enabling therapists to predict
in vitro sensitivity or resistance of an individual
patient's tumours to a cytotoxic drug. We found that
36% of untreated tumours and 13% of pretreated
tumours responded to single agent chemotherapy in
vitro, assuming a colony kill of 70% or more as
sensitive. These numbers correspond well to the
overall percentages in patients under the same
monochemotherapy in vivo (Figure 1).
In our study, we did not observe the increase in
sensitivity to tamoxifen which had been expected
from estimates of hormone receptor concentration
(Jakesz et al., In press). In contrast, we found a
numerical increase in tamoxifen-resistant specimens
among the E2R positive ones. There are no data
indicating that the HTCA is equivalent to the
determination of hormone receptor levels for the
prediction of tumour sensitivity to hormones. To
date, there are insufficient data from which to
derive a consensus on the value of hormone
receptor determination for the prediction of chemo-
sensitivity in women with breast cancer (Lippmann
et al., 1978; Kiang et al., 1978; Dittrich et al.,
1980). The in vitro data of this study demonstrate
that positive E2R levels, are correlated with
resistance to cytotoxic drugs to a statistically
significant degree (P<0.01), thus confirming
Lippman's hypothesis of increasing chemosensitivity
of E2R negative tumours. These data should be the
subject offurther studies.
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The only parameter for ascertaining the value of
an in vitro predictive system is the congruence
between accuracy of in vitro prediction and clinical
course of patients treated accordingly. Information
on this question is scant to date. Sutherland et al.
(1983) reported on two correct resistance
predictions; Jones et al. (1984) described a total of
59 correlations, 22 thereof having been correct
resistance predictions for single agent chemo-
therapy, and 13 correct resistance predictions for
combination chemotherapy. We were able to do 6
in vitro-in vivo correlations; in 4 cases resistance
and in 2 cases, sensitivity were correctly predicted.
In our study, we tried to establish correlations
between factors inherent in patients with breast
cancer, such as tumour size, histopathologic
grading, hormone receptor level, menopausal status,
chemo- and hormone-sensitivity, as well as survival
prognosis on the one hand, and the behaviour of
these patients' tumour cells in the soft agar culture
on the other. Because of the low overall number of
results obtained by this test system at present, any
deployment of the HTCA with the intention of
evaluating chemo- and hormone-sensitivity or of
predicting the prognosis of women with breast
cancer must still be considered investigative.
Attention must be focussed on improving the test
system before the HTCA may be expected to
provide further essential information on the
management ofpatients with breast cancer.
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